Hetero Labs Limited (Unit V) – FDA 483, Aug 12, 2022
An FDA inspection of Hetero Labs Limited (Unit V) in Mahabubnagar, India, a finished dosage manufacturer, revealed significant deficiencies in its quality control unit, including inadequate cleaning validation, process capability assessments, and laboratory investigations. The firm also failed to properly investigate drug complaints, submit a required field alert report, ensure adequate employee training, maintain equipment cleanliness, and implement appropriate computer system controls. These observations indicate a broad range of issues impacting product quality and regulatory compliance.
ID · 86a09275-ffe8-45a7-bdef-0fdf8a394ef9
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.